Prostate Cancer Trial, Recruiting (NCT04146077)

Prostate Cancer Trial, Recruiting NCT04146077 Sponsor: I.M. Sechenov First Moscow State Medical University Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04146077 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed through a biopsy that collected at least 12 tissue samples
People who understand the purpose of the research, agree to take part, and are willing to sign a consent form
People whose prostate cancer is classified as low risk according to European urology guidelines — meaning the cancer is at an early stage (T1–T2a), their PSA blood test result is below 10 ng/ml, and their cancer has the lowest possible aggressiveness score (ISUP grade 1, also known as Gleason score 6)
People where no more than one third of the tissue samples taken during biopsy showed cancer

Who may not be able to join:

People who have already received treatment for prostate cancer
People who have other types of cancer affecting the prostate
People who have other cancer diagnoses
People who are currently taking a type of medication known as 5-alpha-reductase inhibitors (a drug sometimes used for prostate or hair loss conditions) (confirm with trial site)
People who decide they no longer wish to continue in the study
People who decide they would like to start active treatment for their prostate cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04146077

Sponsor: I.M. Sechenov First Moscow State Medical University

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

More information: https://clinicaltrials.gov/study/NCT04146077

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed through a biopsy that collected at least 12 tissue samples
People who understand the purpose of the research, agree to take part, and are willing to sign a consent form
People whose prostate cancer is classified as low risk according to European urology guidelines — meaning the cancer is at an early stage (T1–T2a), their PSA blood test result is below 10 ng/ml, and their cancer has the lowest possible aggressiveness score (ISUP grade 1, also known as Gleason score 6)
People where no more than one third of the tissue samples taken during biopsy showed cancer

Who may not be able to join:

People who have already received treatment for prostate cancer
People who have other types of cancer affecting the prostate
People who have other cancer diagnoses
People who are currently taking a type of medication known as 5-alpha-reductase inhibitors (a drug sometimes used for prostate or hair loss conditions) (confirm with trial site)
People who decide they no longer wish to continue in the study
People who decide they would like to start active treatment for their prostate cancer

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

I.M. Sechenov First Moscow State Medical University

Registry

ClinicalTrials.gov

Start date

1 October 2019

Est. completion

1 October 2024

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

cancer progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov